Erisyon
Commercializing the world's first single-molecule protein sequencer for biomarker discovery and disease detection.
Website: https://www.erisyon.com/
Cover Block
From the public record
| Field | Value |
|---|---|
| Company | Erisyon |
| Tagline | Commercializing the world’s first single-molecule protein sequencer for biomarker discovery and disease detection. [LinkedIn, retrieved 2026] |
| Headquarters | Austin, United States [Crunchbase, retrieved 2026] |
| Founded | 2018 [Crunchbase, retrieved 2026] |
| Stage | Seed [Crunchbase, retrieved 2026] |
| Business model | Hardware + Software |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Academic Spinout |
| Funding label | Seed |
| Total disclosed funding | $188,720 [Technology Networks, May 2020] |
Links
From the public record
- Website: https://www.erisyon.com/
- LinkedIn: https://www.linkedin.com/company/erisyon
- GitHub: https://github.com/erisyon/plaster_v1
The Short Version
PUBLIC Erisyon is an Austin-based biotech spinout building a single-molecule protein sequencing platform, and it merits investor attention because credible trade coverage suggests the company is trying to push proteomics toward the kind of sensitivity and digital readout that made next-generation DNA sequencing commercially important [Genetic Engineering & Biotechnology News, August 2023] [EurekAlert!/UT Austin, October 2018]. The founding story is unusually research-heavy: the underlying fluorosequencing work emerged from the University of Texas at Austin, and public sources tie the company to UT Austin faculty Eric Anslyn and Edward Marcotte, research scientist Angela Bardo, scientist Jagannath Swaminathan, technologist Zack Simpson, and CEO Talli Somekh, who is described as the commercial lead [EurekAlert!/UT Austin, October 2018] [Genetic Engineering & Biotechnology News, August 2023] [Research Bridge Partners, November 2020].
The product claim is ambitious but legible: Erisyon says it is commercializing a platform that sequences individual protein molecules and directly quantifies protein abundance, with early positioning around heterogeneous samples, biomarker discovery, and disease detection [Genetic Engineering & Biotechnology News, August 2023] [Erisyon]. That differentiation remains more technical than commercial at this stage, since public reporting also indicates the company is still developing its instrument and has not announced a launch plan, which makes execution over the next 12 to 18 months less about category storytelling and more about proving reproducible performance and external adoption [Genetic Engineering & Biotechnology News, August 2023].
The team has clear scientific depth, anchored by UT Austin researchers with long proteomics and chemistry pedigrees, while Somekh appears to be carrying the commercialization brief [Research Bridge Partners, November 2020] [Genetic Engineering & Biotechnology News, August 2023]. On the capital side, the company has raised a mix of seed and non-dilutive funding, including a $188,720 Michael J. Fox Foundation grant in May 2020 and a reported $2.05 million seed round announced by Research Bridge Partners in November 2020, alongside CPRIT support reported at $2.2 million in January 2025 [Technology Networks, May 2020] [Research Bridge Partners, November 2020] [Yahoo Finance, January 2025].
The business model appears to be hardware plus software, but public evidence still points to a pre-scale commercialization phase rather than a market-proven instrument business [Crunchbase] [Erisyon]. The practical watch items are straightforward: whether Erisyon can move from scientific promise to a launched product, whether it can show named external users beyond grant-backed validation work, and whether new funding is tied to instrument readiness rather than continued platform development alone [Technology Networks, May 2020] [Erisyon] [Crunchbase].
Single-source, plausible -- Relies on a mix of independent trade coverage, university reporting, investor announcements, and company materials; core company and product claims are partially corroborated, but commercialization timing and several differentiation claims remain company-led.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Seed, with disclosed grant and seed support totaling at least $4,438,720 [Technology Networks, May 2020] [Research Bridge Partners, November 2020] [Yahoo Finance, January 2025] |
The Company in Brief
PUBLIC Erisyon is an Austin, Texas biotechnology company founded in 2018, according to its Crunchbase profile and company website [Crunchbase] [Erisyon]. The public record points to a University of Texas at Austin origin: the company says it is commercializing a single-molecule protein sequencing platform based on fluorosequencing, and its website frames the effort around biomarker discovery and disease detection rather than a broad tools catalog at this stage [Erisyon].
The chronology that can be established from the requested source set is narrow but useful. Crunchbase lists the company in Austin and dates founding to 2018, while the website presents the current operating thesis around protein sequencing and proteomics applications [Crunchbase] [Erisyon]. On financing history, Crunchbase shows seed-stage company status, and the website indicates a focused platform company rather than a services-heavy organization, which is consistent with an academic spinout still moving from core technology development toward commercialization [Crunchbase] [Erisyon].
Single-source, plausible -- Confirmed by Crunchbase and company website, but legal entity details and broader milestone history are not established from the requested source set.
What They Have Built
Mixed sourcing The product story is technically ambitious, but the public record is still closer to platform description than commercial launch detail. Erisyon says it is commercializing a single-molecule protein sequencing platform based on fluorosequencing, a method developed from research at the University of Texas at Austin, and trade coverage describes the system as sequencing individual protein molecules while directly quantifying protein abundance, including in heterogeneous biological samples [EurekAlert!/UT Austin, October 2018] [Genetic Engineering & Biotechnology News, August 2023]. The company also describes the platform as the "world's first single molecule protein sequencer," though that priority claim rests on company-controlled channels and should be read as positioning rather than independent category adjudication [LinkedIn] [Erisyon].
What is better supported is the intended technical wedge. In public materials, Erisyon argues that its platform brings some of the advantages associated with next-generation DNA sequencing to proteomics, specifically high sensitivity, massively parallel throughput, and digital or absolute quantification [Genetic Engineering & Biotechnology News, August 2023] [Erisyon]. Those performance claims are directionally consistent with the underlying fluorosequencing research and with outside coverage of the company's approach, but the public sources reviewed do not provide an announced instrument launch, installed-base data, or third-party benchmark comparisons against incumbent proteomics workflows [Genetic Engineering & Biotechnology News, August 2023] [Will single-molecule protein sequencing be the next generation of proteomics?].
There is at least one concrete software artifact in view, which matters because proteomics platforms live or die on analysis as much as chemistry. A 2024 PLOS Computational Biology paper identifies Erisyon's fluorosequencing data-analysis package, plaster SigProc, as available on GitHub, suggesting the company has exposed part of its signal-processing stack to the research community even while the instrument itself remains in development [PLOS Computational Biology]. That does not establish product maturity on the hardware side, but it does indicate that Erisyon's offering is best understood as hardware plus software, with computational interpretation embedded in the workflow rather than added later.
Single-source, plausible -- Core platform claims are supported by GEN and UT Austin materials, but several performance and category-first assertions rely on company-controlled sources.
Market Size and Demand
Market context
PUBLIC The market matters now because proteomics has reached a familiar inflection point: genomics tools set the benchmark for scale and sensitivity years ago, while protein measurement remains comparatively harder, and that gap is drawing research dollars toward new instrumentation approaches [Genetic Engineering & Biotechnology News, August 2023]. Public materials place Erisyon in the part of life-science tools where buyers are seeking higher-sensitivity proteomics and biomarker measurement, with early application areas that include Parkinson’s biomarker validation and cancer research [Technology Networks, May 2020] [LeadIQ].
The addressable market is best described indirectly, because the available source set does not include a named third-party TAM, SAM, or SOM for Erisyon itself. What is public is the buyer profile and workflow: life-science researchers, biotechnology companies, pharmaceutical companies, and diagnostic-development groups are the likely initial users of a single-molecule protein sequencing platform, according to directory-style market summaries and company-adjacent coverage [LeadIQ] [Genetic Engineering & Biotechnology News, August 2023]. That points to a research-tools entry market first, with any eventual diagnostic market contingent on validation, workflow adoption, and instrument availability, none of which the public record quantifies today [Genetic Engineering & Biotechnology News, August 2023] [Will single-molecule protein sequencing be the next generation of proteomics?].
| Market lens | Public evidence | Read-through for demand |
|---|---|---|
| Proteomics research tools | Proteomics is presented as materially more difficult than genomics, with demand for better sensitivity and direct protein measurement [Genetic Engineering & Biotechnology News, August 2023] | Supports demand for new discovery instruments if they improve signal, throughput, or quantification |
| Biomarker discovery and validation | Parkinson’s biomarker validation was funded by the Michael J. Fox Foundation [Technology Networks, May 2020] | Indicates grant-backed demand in translational research workflows |
| Cancer and immunology research | Public materials tie the platform to cancer research and immuno-oncology-oriented work, though some of this is company-adjacent rather than independently reported [Technology Networks, May 2020] [LinkedIn, retrieved 2026] | Suggests adjacent oncology demand, but commercial pull is less firmly evidenced |
| Diagnostic development | Directory-style summaries include diagnostic-development groups among target users [LeadIQ] | Plausible long-term segment, but current public evidence is earlier-stage than commercial diagnostics |
The table shows a market forming around research and translational use cases rather than proven clinical deployment. For investors, that usually means the nearer revenue pool sits in instruments, assays, and software used by research labs before any diagnostic market becomes tangible.
Demand drivers in the cited research are straightforward. First, Erisyon’s proposition is tied to direct protein abundance measurement in heterogeneous biological samples, a capability that trade coverage treats as meaningful because proteins, unlike DNA, are harder to infer cleanly from upstream signals [Genetic Engineering & Biotechnology News, August 2023]. Second, the public grant history suggests external funders see value in higher-sensitivity biomarker work, particularly in neurodegeneration, where earlier detection remains an active unmet need [Technology Networks, May 2020]. Third, collaborative research and validation projects aimed at translating single-molecule proteomics into biomarker discovery indicate that the market pull may initially come through co-development and method validation rather than broad catalog sales [MTEC].
The nearest adjacent markets are established proteomics tools, next-generation sequencing-inspired life-science instrumentation, and biomarker discovery platforms. Erisyon’s own framing is that it brings some of the advantages associated with next-generation DNA sequencing into proteomics, which places it less as a substitute for genomics and more as an attempt to extend similar scale economics and digital readout into protein analysis [Erisyon, retrieved 2026] [Genetic Engineering & Biotechnology News, August 2023]. Substitutes for buyers therefore include incumbent proteomics methods and broader biomarker-discovery workflows, especially where a lab may prefer a known assay stack over adopting a new instrument category. Public sources do not name those incumbents directly, so the competitive pressure is better understood as methodological inertia than head-to-head displacement on the present record [Genetic Engineering & Biotechnology News, August 2023].
Regulatory and macro factors cut in two directions. On the favorable side, non-dilutive funding from disease foundations and public-sector sources suggests that translational proteomics can attract grant capital before large-scale commercialization, which can lengthen runway for deeptech biology companies [Technology Networks, May 2020] [Yahoo Finance, January 2025]. On the constraining side, public reporting also says Erisyon is still developing an instrument and has not announced launch plans, which means market timing remains coupled to technical validation, manufacturing readiness, and buyer workflow integration rather than category interest alone [Will single-molecule protein sequencing be the next generation of proteomics?]. That is typical for frontier life-science tools: the market can be real before revenue is broad, but adoption usually waits for instrument reliability and repeatable data in external hands.
Single-source, plausible -- Based primarily on one independent trade feature, one grant announcement, and directory-style market descriptions; market sizing is qualitative rather than quantified by a named third-party report.
Who Else Is Fighting for This
MIXED Erisyon appears to be positioned less against a clearly disclosed list of direct commercial peers than against a broad set of alternative proteomics workflows, with its public case resting on a different measurement architecture rather than on announced go-to-market traction [Genetic Engineering & Biotechnology News, August 2023] [Erisyon, retrieved 2026].
The segment map matters here because the competitive set changes depending on the job to be done. For biomarker discovery and translational research, Erisyon is competing first with established proteomics methods already embedded in academic and pharmaceutical labs, not just with other single-molecule sequencing startups. Public materials say the platform is designed to sequence individual protein molecules and quantify abundance directly, including in heterogeneous samples, which puts it in the part of the market where sensitivity and direct counting are the pitch [Genetic Engineering & Biotechnology News, August 2023]. The same sources tie current use cases to Parkinson's biomarker validation and cancer research, which suggests the company is still competing for research budgets and validation projects rather than displacing a standard clinical workflow at scale [Technology Networks, May 2020].
Its edge today looks strongest in technical origin and founder-market fit, but weaker in distribution. The underlying fluorosequencing work came out of the University of Texas at Austin, and public sources connect multiple co-founders, including Edward Marcotte, Eric Anslyn, Angela Bardo, and Jagannath Swaminathan, to that scientific base [EurekAlert!/UT Austin, October 2018] [Genetic Engineering & Biotechnology News, August 2023] [Research Bridge Partners, November 2020]. That can be durable if the defensibility sits in licensed IP, hard-won assay know-how, and software built around the workflow, including the publicly referenced plaster SigProc analysis package [PLOS Computational Biology, 2024]. It is more perishable if the advantage depends mainly on being early with a compelling scientific narrative, because public reporting also indicates the company is still developing an instrument and had not announced launch plans in the reviewed coverage [Genetic Engineering & Biotechnology News, August 2023].
The main exposure is practical rather than conceptual. No named commercial customers or completed instrument deployments were identified in the reviewed public material, and the company has not publicly established that it owns a procurement channel into pharma, diagnostics, or core lab buyers [Austin Community College Bioscience Incubator, September 2021] [Technology Networks, May 2020]. That leaves Erisyon exposed to adjacent substitutes with existing lab footprint, validated workflows, and purchasing familiarity, even if those alternatives do not match its single-molecule claims on paper [Genetic Engineering & Biotechnology News, August 2023]. In other words, the near-term competitor may be the incumbent tool already budgeted by the researcher, not a named startup building a similar machine.
The most plausible 18-month scenario is a sorting process between companies that can convert scientific novelty into repeatable external use and those that remain in extended validation. In that setup, University of Texas at Austin is the most visible winner if the science continues to validate, because successful translation would further confirm the commercial value of the licensed research base [EurekAlert!/UT Austin, October 2018]. Erisyon is the clearest loser if instrument readiness or outside-user access slips, since public evidence today supports scientific promise and grant-backed validation work, but does not yet show a disclosed launch, installed base, or customer adoption curve [Technology Networks, May 2020] [Austin Community College Bioscience Incubator, September 2021] [Genetic Engineering & Biotechnology News, August 2023].
Opportunity
Upside case
PUBLIC The prize here is not a better assay at the margin, but a plausible new instrumentation layer for proteomics if Erisyon can turn fluorosequencing from a research breakthrough into a repeatable commercial workflow [Genetic Engineering & Biotechnology News, August 2023] [EurekAlert!/UT Austin, October 2018].
The headline opportunity is straightforward. If Erisyon can make single-molecule protein sequencing usable outside its founding lab context, it could become one of the first category-defining platforms in high-sensitivity proteomics, first for biomarker discovery and validation, and later for disease detection and drug-development workflows [Genetic Engineering & Biotechnology News, August 2023] [Technology Networks, May 2020]. That is reachable, not merely aspirational, because the public record shows three ingredients already in place: the core method originated in a major academic research program at UT Austin, the company has a licensing path to commercialize it, and outside funders have already supported disease-focused validation work rather than only basic research [EurekAlert!/UT Austin, October 2018] [Technology Networks, May 2020] [Research Bridge Partners, November 2020]. The constraint is that public sources still describe Erisyon as developing an instrument rather than shipping a broadly available one, so the upside depends on productization and external adoption rather than on discovery alone [Genetic Engineering & Biotechnology News, August 2023].
The upside branches into a small number of concrete paths, and each path has a visible catalyst in the public record.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Biomarker engine for neurodegeneration and oncology | Erisyon becomes a preferred platform for hard-to-measure biomarker validation in research and translational medicine | A funded disease program produces reproducible data that other groups want to extend | The company has already been funded by the Michael J. Fox Foundation for Parkinson's biomarker work, and public materials also point to cancer-related applications [Technology Networks, May 2020] [MTEC] |
| Core instrument for translational proteomics labs | Erisyon's instrument becomes a standard purchase for leading academic and biopharma proteomics groups | External launch of the instrument, followed by early reference users | Trade coverage says the company is developing an instrument, while its platform is positioned as bringing next-generation sequencing style throughput and quantification to proteins [Genetic Engineering & Biotechnology News, August 2023] [Erisyon] |
| Software-plus-workflow platform around fluorosequencing | Erisyon expands from hardware into analysis software and assay workflows, raising switching costs over time | Wider use of its signal-processing stack by collaborators and early users | Public literature identifies its plaster SigProc analysis package on GitHub, which suggests the company is building around both data generation and interpretation rather than instrument hardware alone [PLOS Computational Biology] |
The compounding logic is better than it first appears, assuming the instrument works as advertised in outside hands. Single-molecule proteomics is not just a box sale. Each run can generate hard-to-recreate data, each disease program can sharpen assay design, and each external collaboration can improve both the commercial narrative and the analysis stack [Genetic Engineering & Biotechnology News, August 2023] [PLOS Computational Biology]. That creates a modest but real flywheel: more validation studies can attract more research users, more users can produce more diverse samples and edge cases, and that in turn can improve software, protocols, and confidence in the platform's absolute quantification claims [Technology Networks, May 2020] [Erisyon]. The public evidence that this flywheel has started is early, but visible, in the combination of grant-backed biomarker work, incubator participation, and a public software package tied to fluorosequencing workflows [Technology Networks, May 2020] [Austin Community College Bioscience Incubator] [PLOS Computational Biology].
The size of the win is large enough to matter even after discounting heavily for execution risk. A useful comparable is not a direct one-to-one peer, but the genomics-toolkit playbook that built durable value around instruments, consumables, and data workflows. If Erisyon were to become an established platform in translational proteomics with recurring software and workflow revenue layered on top of instrument adoption, the outcome could support a venture-scale company worth hundreds of millions of dollars, potentially more than $1 billion in an aggressive adoption case (scenario, not a forecast). The justification from public evidence is narrower than that headline number: UT-originated science, early non-dilutive validation funding, seed backing from a specialized investor, and a product thesis that addresses a real measurement gap between genomics-style scale and current protein analysis methods [EurekAlert!/UT Austin, October 2018] [Technology Networks, May 2020] [Research Bridge Partners, November 2020] [Genetic Engineering & Biotechnology News, August 2023]. What is still missing from the public record is the proof point that usually narrows the valuation band, namely named customers, commercial deployments, or instrument launch timing.
Single-source, plausible -- This section relies mainly on named trade, institutional, and company sources, with partial corroboration for the technology origin and grant-funded use cases, but limited independent public evidence on commercial adoption or scale.
Sources
From the public record
[LinkedIn, retrieved 2026] Erisyon | LinkedIn | https://www.linkedin.com/company/erisyon
[Crunchbase, retrieved 2026] Erisyon - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/erisyon
[Technology Networks, May 2020] Erisyon Awarded Michael J. Fox Foundation Grant To Validate Methods for Early Parkinson’s Detection | https://www.technologynetworks.com/cancer-research/product-news/erisyon-awarded-michael-j-fox-foundation-grant-to-validate-methods-for-early-parkinsons-detection-334527
[Genetic Engineering & Biotechnology News, August 2023] Protein Sequencing Expands the Omics Club | https://www.genengnews.com/topics/drug-discovery/protein-sequencing-expands-the-omics-club/
[EurekAlert!/UT Austin, October 2018] New protein sequencing method could transform biological research | https://www.eurekalert.org/news-releases/487442
[Research Bridge Partners, November 2020] Research Bridge Partners Makes Seed Capital Investment in Erisyon Inc. | https://www.researchbridgepartners.org/research-bridge-partners-makes-seed-capital-investment-in-erisyon-inc/
[Erisyon, retrieved 2026] Erisyon | https://www.erisyon.com/
[Yahoo Finance, January 2025] Erisyon Receives CPRIT Product Development Award | https://finance.yahoo.com/news/erisyon-receives-cprit-product-development-140000000.html
[PLOS Computational Biology, 2024] plaster: a cloud-computing platform for analysis of fluorosequencing data | https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1011997
[LeadIQ, retrieved 2026] Erisyon | https://leadiq.com/c/erisyon/5ed241c78a998f161e369640
[MTEC, retrieved 2026] Erisyon | https://mtec-sc.org/members/erisyon/
[Austin Community College Bioscience Incubator, September 2021] All About Proteins with Erisyon | https://sites.austincc.edu/incubator/all-about-proteins-with-erisyon/
Articles about Erisyon
- Erisyon's Single-Molecule Protein Sequencer Aims to Unlock the Next Omics — The Austin-based spinout, backed by CPRIT and the Michael J. Fox Foundation, is commercializing a novel 'fluorosequencing' technique to quantify proteins one molecule at a time.